Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
The drug may not become available to patients for a number of years yet, but researchers believe that if clinical trials are successful, it could be used to tackle a variety of treatment-resistant cancers.
Patients with breast cancer for example frequently become resistant to existing hormone-based treatments, leading to the disease becoming fatal.
In a bid to come up with new forms of treatment that work in a distinct way from established ones, chemists, biologists and clinicians at Imperial College London collaborated on creating a new drug, the properties of which are reported in the journal Molecular Cancer Therapeutics.
The team of scientists at Imperial was funded by Cancer Research UK. The drug was then developed by Imperial, in collaboration with Emory University in the USA.
Early lab-based tests of ICEC0942 were successful in targeting resistant breast cancers and indicated minimal side effects. ICEC0942 was then licenced to Carrick Therapeutics, who developed it into a molecule named CT7001, which they have taken to early-stage clinical trials in less than two years.
The first patient was given
Article originally posted at